High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut (Reuters) - In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer. Its stock tripled in the past year.